Association of Celiac Disease With Pembrolizumab

Immune checkpoint inhibitors (ICIs) in the recent times have transformed the landscape of the management of many solid tumors. Unfortunately, many immune-related adverse effects are associated with ICIs, which lead to a negative outcome in cancer treatment. We present a case of a 63-year-old female...

Descripción completa

Detalles Bibliográficos
Autores principales: Sethi, Ashish, Helfand, Alexander, Balikani, Lame, Bunker, Mark, Finley, Gene
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2021
Materias:
Internal Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8272441/
https://www.ncbi.nlm.nih.gov/pubmed/34277188
http://dx.doi.org/10.7759/cureus.15565
_version_ 1783721219318611968
author Sethi, Ashish
Helfand, Alexander
Balikani, Lame
Bunker, Mark
Finley, Gene
author_facet Sethi, Ashish
Helfand, Alexander
Balikani, Lame
Bunker, Mark
Finley, Gene
author_sort Sethi, Ashish
collection PubMed
description Immune checkpoint inhibitors (ICIs) in the recent times have transformed the landscape of the management of many solid tumors. Unfortunately, many immune-related adverse effects are associated with ICIs, which lead to a negative outcome in cancer treatment. We present a case of a 63-year-old female with metastatic adenocarcinoma of unknown origin, who developed celiac disease during the course of treatment with pembrolizumab. Association of celiac disease with this form of immunotherapy has never been documented before.
format Online
Article
Text
id pubmed-8272441
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Cureus
record_format MEDLINE/PubMed
spelling pubmed-82724412021-07-15 Association of Celiac Disease With Pembrolizumab Sethi, Ashish Helfand, Alexander Balikani, Lame Bunker, Mark Finley, Gene Cureus Internal Medicine Immune checkpoint inhibitors (ICIs) in the recent times have transformed the landscape of the management of many solid tumors. Unfortunately, many immune-related adverse effects are associated with ICIs, which lead to a negative outcome in cancer treatment. We present a case of a 63-year-old female with metastatic adenocarcinoma of unknown origin, who developed celiac disease during the course of treatment with pembrolizumab. Association of celiac disease with this form of immunotherapy has never been documented before. Cureus 2021-06-10 /pmc/articles/PMC8272441/ /pubmed/34277188 http://dx.doi.org/10.7759/cureus.15565 Text en Copyright © 2021, Sethi et al. https://creativecommons.org/licenses/by/3.0/This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Internal Medicine
Sethi, Ashish
Helfand, Alexander
Balikani, Lame
Bunker, Mark
Finley, Gene
Association of Celiac Disease With Pembrolizumab
title Association of Celiac Disease With Pembrolizumab
title_full Association of Celiac Disease With Pembrolizumab
title_fullStr Association of Celiac Disease With Pembrolizumab
title_full_unstemmed Association of Celiac Disease With Pembrolizumab
title_short Association of Celiac Disease With Pembrolizumab
title_sort association of celiac disease with pembrolizumab
topic Internal Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8272441/
https://www.ncbi.nlm.nih.gov/pubmed/34277188
http://dx.doi.org/10.7759/cureus.15565
work_keys_str_mv AT sethiashish associationofceliacdiseasewithpembrolizumab
AT helfandalexander associationofceliacdiseasewithpembrolizumab
AT balikanilame associationofceliacdiseasewithpembrolizumab
AT bunkermark associationofceliacdiseasewithpembrolizumab
AT finleygene associationofceliacdiseasewithpembrolizumab

Ejemplares similares